Y
Yi-Bin Chen
Researcher at Harvard University
Publications - 148
Citations - 5234
Yi-Bin Chen is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 30, co-authored 129 publications receiving 3484 citations.
Papers
More filters
Journal ArticleDOI
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
Zachariah DeFilipp,Patricia P. Bloom,Mariam Torres Soto,Michael K. Mansour,Mohamad R. Abdul Sater,Miriam H. Huntley,Sarah E Turbett,Raymond T. Chung,Yi-Bin Chen,Elizabeth L. Hohmann +9 more
TL;DR: Two patients in whom extended-spectrum beta-lactamase-producing Escherichia coli bacteremia occurred after they had undergone FMT are described; both cases were linked to the same stool donor by means of genomic sequencing.
Journal ArticleDOI
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids,Haesook T. Kim,Pavan Bachireddy,Caitlin Costello,Rebecca Liguori,Alexandra Savell,Alexander Lukez,David Avigan,Yi-Bin Chen,Peter McSweeney,Nicole R. LeBoeuf,Michael S. Rooney,Michaela Bowden,Chensheng W. Zhou,Scott R. Granter,Jason L. Hornick,Scott J. Rodig,Masahiro Hirakawa,Mariano Severgnini,F. Stephen Hodi,Catherine J. Wu,Catherine J. Wu,Vincent T. Ho,Corey Cutler,John Koreth,Edwin P. Alyea,Joseph H. Antin,Philippe Armand,Howard Streicher,Edward D. Ball,Jerome Ritz,Asad Bashey,Robert J. Soiffer +32 more
TL;DR: Early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred.
Journal ArticleDOI
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.
Andrew C. Harris,Andrew C. Harris,Rachel Young,Rachel Young,Steven M. Devine,William J. Hogan,Francis Ayuk,Udomsak Bunworasate,Chantiya Chanswangphuwana,Yvonne A. Efebera,Ernst Holler,Mark R. Litzow,Rainer Ordemann,Muna Qayed,Anne S. Renteria,Ran Reshef,Matthias Wölfl,Yi-Bin Chen,Steven A. Goldstein,Madan Jagasia,Franco Locatelli,Stephan Mielke,David L. Porter,Tal Schechter,Zhanna Shekhovtsova,James L.M. Ferrara,John E. Levine,John E. Levine +27 more
TL;DR: This paper developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of acute graft-versus-host disease (GVHD) for use in a large international GVHD research consortium.
Journal ArticleDOI
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly,Marcelo C. Pasquini,Michael Martens,Ruta Brazauskas,Xiaochun Zhu,Kehinde Adekola,Mahmoud Aljurf,Karen K. Ballen,Ashish Bajel,Frédéric Baron,Minoo Battiwalla,Amer Beitinjaneh,Jean-Yves Cahn,Mathew Carabasi,Yi-Bin Chen,Saurabh Chhabra,Stefan O. Ciurea,Edward A. Copelan,Anita D'Souza,John R. Edwards,James M. Foran,Cesar O. Freytes,Henry C. Fung,Robert Peter Gale,Sergio Giralt,Shahrukh K. Hashmi,Gerhard C. Hildebrandt,Vincent T. Ho,Ann A. Jakubowski,Hillard M. Lazarus,Marlise R. Luskin,Rodrigo Martino,Richard T. Maziarz,Philip L. McCarthy,Taiga Nishihori,Rebecca L. Olin,Richard F. Olsson,Richard F. Olsson,Attaphol Pawarode,Edward Peres,Andrew R. Rezvani,David A. Rizzieri,Bipin N. Savani,Harry C. Schouten,Mitchell Sabloff,Matthew D. Seftel,Sachiko Seo,Mohamed L. Sorror,Mohamed L. Sorror,Jeff Szer,Baldeep Wirk,William A. Wood,Andrew S. Artz +52 more
TL;DR: Over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥70 years with hematologic malignancies across the United States.
Journal ArticleDOI
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson,Bradley D. Hunter,Robert A. Redd,Scott J. Rodig,Pei Hsuan Chen,Kyle Wright,Mikel Lipschitz,Jerome Ritz,Yusuke Kamihara,Philippe Armand,Sarah Nikiforow,Michael Rogalski,Joseph E. Maakaron,Samantha Jaglowski,Marcela V. Maus,Yi-Bin Chen,Jeremy S. Abramson,Justin Kline,Elizabeth Budde,Alex F. Herrera,Matthew Mei,Jonathon B. Cohen,Stephen D. Smith,David G. Maloney,Ajay K. Gopal,Matthew J. Frigault,Utkarsh Acharya,Utkarsh Acharya +27 more
TL;DR: Axi-cel yields similar rates of overall response and toxicity in commercial and trial settings, although CR rates and DOR were more favorable in patients eligible for ZUMA-1.